Compare Repligen Corporation Common Stock (RGEN) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Global X Defense Tech ETF — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while Global X Defense Tech ETF trades at $59.55 (market cap $6.34B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Global X Defense Tech ETF for 45 Days on average.
| RGEN | SHLD | |
|---|---|---|
Market Cap | $11.14B | $6.34B |
Volume | 1,259,263 | 1,202,620 |
Sector | Health | Sector/Thematic |
52-Week High | $194.57 | $78.02 |
52-Week Low | $102.87 | $58.20 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SHLD (Global X Defense Tech ETF) trades at $59.34, down 0.82% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF focuses on defense technology and cybersecurity with global diversification beyond U.S. names. Recent institutional buying includes Focus Financial Network increasing its stake by 55.4% in Q2 2026 (SEC filing, August 2026) and Balefire LLC's new $1.12 million position.
Geopolitical tensions and rising global defense budgets support long-term growth potential, though the ETF faces competition from broader aerospace funds and sensitivity to defense policy changes. The current technical weakness near support at $58-59 presents a potential entry point for investors bullish on defense tech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
